1 min read

Shortening Development and Approval Timelines for Novel Medicinal Products

The FDA and EMA offer expedited regulatory approval pathways to accelerate time-to-market for novel therapies intended to treat serious conditions and unmet medical needs. There are twelve special designations, many of which reduce clinical development and approval timelines. However, these are not always granted.

In this infographic, Veristat regulatory experts highlight the benefits of, qualifying criteriaDownload the Infographic for, and timing and procedures for twelve expedited programs and designations. Companies must build a strategic regulatory plan and leverage the right pathways to ensure a seamless regulatory strategy and submission plan for both U.S. and global registrations. Overall, these expedited regulatory pathways can save time and reduce the cost of bringing therapies to market—and to patients—sooner.

Download the infographic to learn more about the benefits of these key special designations:

  • Orphan Drug Designation
  • Breakthrough Therapy (BT)
  • PRIority MEdicines (PRIME)
  • Fast Track (FT)
  • Qualified Infectious Disease Product Designation (QIDP)
  • Regenerative Medicine Advanced Therapy (RMAT)
  • Priority Review (PR)
  • Accelerated Approval
  • Emergency Use Authorization (EUA)
  • Accelerated Assessment (AA)
  • Conditional Marketing Authorization (CMA)
  • Real Time Oncology Review (RTOR)

Download Now


Screen Shot 2022-11-05 at 12.20.20 PM


Meet Veristat. Learn More.


Laying the Groundwork to Measure the Impact of Decentralized Clinical Trials (DCTs)

The Tufts CSDD Roundtable took place in November, and on behalf of Veristat, I was honored to participate in this invite-only program. It is part of...

Read More

1 min read

On-Demand Webinar: Orphan Drug Designation - The Considerations, The Rewards, and How They Differ Between The US and Europe

Did you know approximately 1 in 10 Americans are affected by a rare disease or condition according to the National Institutes of Health (NIH)? That’s...

Read More

Rolling Review mechanisms and CMAs (Conditional Marketing Authorisations) have made it possible to speed up the approval of treatments against Covid-19

GENESIS BIOMED recently interviewed Xavier Luria, former Head of Safety and Efficacy of Medicines at the European Medicines Agency (EMA), and now...

Read More